Indication

Blasts Under 10 Percent of Bone Marrow Nucleated Cells

1 clinical trial

1 product

Clinical trial

PD-1 Inhibition With Nivolumab for the Treatment of Patients With Acute Myeloid Leukemia in Remission at High Risk for Relapse

Status: Completed, Estimated PCD: 2023-08-08

Product